Top Banner
An informa business www.citeline.com SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development
14

An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

Mar 27, 2015

Download

Documents

Grace Quinlan
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

SLA Pipeline Town Hall Meeting

Christine Blazynski PhDSr. Vice-President

Product Development

Page 2: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

TrialTroveClinical Trials Intelligence

Integrated and Enterprise-Wide ServicesPipeline / Pharmaprojects

Drug Intelligence

All Drugs InDevelopmentFrom BenchTo Market

TrialPredictTrials Timing / Benchmarking

Citeline Proprietary

Prediction of Trials Enrollment

Timing

World’s foremost collection

of

clinical trials,investigators, sites,

drugs & analysis

Global Coverage

Of Clinical Trials Design and Status

SiteTroveInvestigator / Site Selection

Investigators And Sites

Based UponDirect TrialsExperience

Citeline AnalyticsMapping the Competition

Map Date:

6/23/07 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

Adjuvant

Phase II Biomarker/Tox

Phase III Biomarker/SE, PGX

EI, Biomarker/SE, PGX

Neoadjuvant

Phase II Biomarker/SE

PGX

Biomarker/SE

Biomarker/SE

Biomarker/SE

PGX

Biomarker/SE

Biomarker/SE

Phase III Biomarker/SE, PGX

PGX

NeoAdjuvant and Adjuvant

Phase II Biomarker/Tox

2010 2011

Competitive Development Map

20142012 201320052004

Drug: Tykerb (Lapatinib)Disease: Breast CancerAdjuvant and Neoadjuvant Therapy

2006 2007 2008 2009

Lap +Tras (+ AC,Doxo,Pac,Surg), 0/I/II/III, TA100, #70768

Lap, I/II/III, TA150, #52438

Lap, I/II/III, TA120, #45628

Lap (+ AC,Doc,Doxo), II/III, TA71, #60281

Lap (+/vs Tras, + Chemo), II/III, TA120, #63895

Lap (+/vs Tras, + Pac), I/II, TA450, NEO-ALTTO, (#53035)

Lap (+/vs Tras, +AC,Doxo), II/III, TA522, #71240

Lap (+/vs Let), II/III, TA91, #63171

Lap, II/III, #51923

Lap, II/III/IV, TA22-55, #33321

Lap (+ AC,Doxo,Pac,Tras), 0/I/II/III, TA109, #65110

Lap (4-arm trial), I/II, TA8000, ALTTO, (#45399)

Lap, I/II/III, TA3000, TEACH, (#56312)

Lap (+/vs Tras, + AC,Doxo), I/II, #55823

Lap (+ Pac,Surg), III/IV, AA50/TA60, #29064

Lap (+ Ab), I/II/III, TA30, #50405

Visualization ofClinical

DevelopmentPrograms

Page 3: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Depth and Breadth of Citeline Data

150 countries covered 180+ disease areas in TrialTrove/ >1000 in Pipeline

☐ 222 therapeutic categories in Pipeline 250+ analysts and editors 18,000 data sources >4,000 companies developing therapeutics >46,000 drugs

☐ Over 30 years of history >120,000 interventional trials >250,000 investigator profiles

Page 4: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Citeline’s Drug Intelligence

One centralized database of drug information

Deep integration with Citeline’s clinical development offerings

Page 5: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Pharmaprojects

Legacy pipeline database☐ PJB publications

Thirty-one continual years of tracking drug development☐ Print 3rd party electronic distributer CD ROM Web

delivery☐ Updated once weekly

Trends data from 1995 through 2010

Page 6: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Pipeline

Continually updated/real-time

Clean, simple, user-friendly interface

Customized alerts, saved searches, and share search

Unlimited research support

Search criteria expanded over time

All fields export or disease-focused export

Integration with TrialTrove, SiteTrove and TrialPredict

Page 7: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Export Options

Page 8: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Page 9: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Recent Enhancements

☐ Hierarchical mechanism search

☐ Addition of biosimilars/biogenerics

☐ Company country HQ search and research focus

☐ Delivery route/medium/technology search

☐ Advanced search [phase 1]

☐ Automatic search for trials from multiple drug results

☐ Search by latest change date or range

Page 10: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Pipeline

Page 11: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Planned Enhancements

☐ Advanced Search: nested booleans, ability to move search terms, edit operators within and between categories

☐ NCE search

☐ Search by chemical name

☐ Search by originator OR licensee

☐ Trial reporting: tabular view

☐ Dashboard reporting

Page 12: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Page 13: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Citeline’s Drug Intelligence

One centralized database of drug information

Drug, company data to meet all business development needs

Page 14: An informa business  SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.

An informa business www.citeline.com

Citeline - MedTrack MedTrack joined Citeline in late March 2011. As of April 6:

☐ 21,326 companies☐ 107,199 drugs (not all unique; includes generics)☐ 1,556 drug delivery technologies☐ 55,758 deals☐ 642 indications☐ 615,114 searchable news releases☐ 142,525 management bios☐ 481,558 searchable SEC documents

MedTrack V2 migration continues Planning for initial integration between products just starting but clear

synergies exist Need for market research and focus groups……… will you help?